Global Respiratory Syncytial
Virus (RSV) diagnostics market is expected to reach USD 1.2 billion by 2022,
according to a new study by Grand View Research Inc. Increasing neonatal
population suffering from respiratory conditions including RSV infections and
supportive initiatives for diagnosis of newborns by the healthcare providers
are expected to be vital impact rendering drivers for RSV diagnostics market.
According to the statistics
provided by the WHO, hospitalization of over 150,000 children (below the age of
five) and about 14,000 deaths in geriatric patients occurred in the U.S. in
2014 due to RSV infections. This is anticipated to trigger demand for testing
of these conditions over the forecast period.
Furthermore, the global birth
rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to
increase the infant population substantially over the next seven years.
According to the statistics, it is estimated that about 134.2 million births
took place in 2014, which are prone to RSV infections and require diagnosis,
thus forming a large market base.
In 2010, Save Babies Through
Screening Foundation (SBTS) entered in a partnership with World Solutions
Against Infectious Disease (WSAID) as an attempt to promote higher screening of
newborns for infectious diseases, metabolic disorders, and hearing
disabilities.
In depth research report on Respiratory Syncytial Virus
Diagnostics Market
Further key findings from the study suggest:
·
Chromatographic immunoassay
technology based products are expected to witness the fastest growth at a CAGR
above 10.0% over the next seven years owing to their higher specificity than
molecular diagnostic products. The commercially available test kits include
Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
·
Hospitals are predicted to
dominate the RSV diagnostics market followed by home care. Together, they are
expected to contribute over 50.0% of the market share in 2022. Increasing
demand for home care diagnostic devices by patients is anticipated to drive
growth of the segment over the next seven years.
·
North America is anticipated to
dominate the market and contribute a revenue share of over 40.0% by 2022.
Rising awareness among the population base and favorable initiatives by the
government agencies such as the WHO, PAHO, and WSAID to initiate and implement
newborn screening are expected to drive growth.
·
Key players of the market
include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics,
Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA
waiver and launch of RSV assays by companies like Roche Diagnostics, Becton
Dickinson and Company, and Alere Inc. are expected to boost market growth over
the forecast period.
Grand View Research has
segmented the Global Respiratory Syncytial Virus diagnostics market on the
basis of products, end-use, and region:
RSV Diagnostics Market Product Outlook (Revenue, USD Million,
2012 - 2022)
·
Direct Fluorescence Antibody
(DFA) Method
·
Rapid Antigen Diagnostic Tests
(RADTs)
·
Molecular Diagnostics
·
Chromatographic Immunoassay
·
Diagnostic Imaging
·
Gel Microdroplets
·
Flow Cytometry
·
Others
RSV Diagnostics Market End-use Outlook (Revenue, USD
Million, 2012 - 2022)
·
Hospitals
·
Laboratory
·
Clinics
·
Homecare
RSV Diagnostics Market Regional Outlook (Revenue, USD
Million, 2012 - 2022)
·
North America
·
U.S.
·
Canada
·
Europe
·
UK
·
Germany
·
France
·
Spain
·
Italy
·
Asia Pacific
·
Japan
·
China
·
India
·
Latin America
·
Brazil
·
Mexico
·
Argentina
·
Peru
·
MEA
·
South Africa
·
Saudi Arabia
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment